Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.58 EUR | +1.32% |
|
+1.85% | +13.11% |
| Market Cap | 12.33B 14.08B 11.45B 10.52B 19.83B 1,358B 20.12B 136B 53.39B 665B 52.84B 51.7B 2,296B | P/E 2026 * |
24.2x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 15.74B 17.96B 14.61B 13.43B 25.3B 1,733B 25.67B 174B 68.12B 848B 67.43B 65.97B 2,930B | EV / Sales 2026 * |
2.07x | EV / Sales 2027 * | 1.91x |
| Free-Float |
58.35% | Yield 2026 * |
1.09% | Yield 2027 * | 1.26% |
Last Transcript: Eurofins Scientific SE
| 1 day | +1.32% | ||
| 1 week | +1.85% | ||
| Current month | +2.95% | ||
| 1 month | +11.18% | ||
| 3 months | +12.68% | ||
| 6 months | -1.09% | ||
| Current year | +13.11% |
| 1 week | 69 |  | 71.28 |
| 1 month | 65.58 | | 71.28 |
| Current year | 56.84 | | 74.32 |
| 1 year | 54.86 | | 74.32 |
| 3 years | 39.47 | | 74.32 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 27/4/26 | Buy | 700 | 0.0004% | |||
| 19/4/26 | Fiscal year | Executive/Senior Manager | 700 | 0.0004% | ||
| 19/4/26 | Sell | Executive/Senior Manager | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.32% | +1.85% | +11.40% | +15.52% | 13.89B | |
| -4.89% | -7.74% | -3.35% | +9.27% | 48.5B | |
| -0.14% | -0.76% | +378.26% | +583.71% | 38.97B | |
| +0.39% | +2.79% | +8.23% | +61.99% | 35.43B | |
| -1.54% | -4.01% | +5.95% | -13.03% | 33.65B | |
| -0.87% | -3.19% | -1.27% | +29.16% | 26.58B | |
| -1.28% | -6.20% | - | - | 16.82B | |
| -0.67% | -0.21% | +10.55% | +115.31% | 15.18B | |
| +0.40% | -2.79% | +3.58% | -31.98% | 12.76B | |
| -1.79% | -3.67% | +1,196.63% | +600.24% | 11.56B | |
| Average | -0.91% | -1.77% | +178.89% | +152.24% | 25.33B | |
| Weighted average by Cap. | -1.31% | -1.78% | +123.57% | +144.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.6B 8.67B 7.06B 6.48B 12.22B 837B 12.4B 84.06B 32.9B 410B 32.56B 31.86B 1,415B | 8.07B 9.21B 7.49B 6.88B 12.97B 888B 13.16B 89.22B 34.92B 435B 34.56B 33.82B 1,502B |
| Net income | 522M 595M 484M 445M 838M 57.44B 851M 5.77B 2.26B 28.11B 2.23B 2.19B 97.09B | 665M 759M 617M 567M 1.07B 73.25B 1.08B 7.36B 2.88B 35.84B 2.85B 2.79B 124B |
| Net Debt | 3.4B 3.88B 3.16B 2.9B 5.47B 375B 5.55B 37.65B 14.73B 183B 14.58B 14.27B 634B | 3.07B 3.51B 2.85B 2.62B 4.94B 338B 5.01B 33.97B 13.3B 166B 13.16B 12.88B 572B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/07/26 | €70.58 | +1.32% | 294,950 |
| 21/07/26 | €69.66 | -2.03% | 223,691 |
| 20/07/26 | €71.10 | +1.17% | 262,758 |
| 17/07/26 | €70.28 | +1.12% | 272,834 |
| 16/07/26 | €69.50 | +0.29% | 169,938 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
